PTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to PTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

PTC Therapeutics (PTCT) Misses Q3 EPS by 30c, Revenues Miss

October 29, 2019 4:54 PM EDT

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.06), $0.30 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $71.42 million versus the consensus estimate of $73.02 million.

Third Quarter 2019 Financial Highlights:

Total revenues were $71.4 million for the third quarter of 2019, compared to $53.6 million for the third quarter of 2018.Translarna net product revenues were $48.3 million for the third quarter of 2019, compared to $30.4 million for the third quarter of 2018. These results reflect the expanded commercialization of Translarna.Emflaza® net product revenues were $22.9 million for the third quarter of 2019, compared to... More